Loading...
•
Mar 31, 2022
Bio-Rad Q1 2022 Earnings Report
Bio-Rad's financial performance decreased compared to the same period last year, but the underlying core business showed strength as COVID-related contributions subsided.
Key Takeaways
Bio-Rad Laboratories reported a decrease in first-quarter net sales by 3.7% compared to the previous year, with sales totaling $700.1 million. The decline was partially attributed to lower COVID-19 related revenue, though excluding these sales, revenue increased by 6.5% on a currency-neutral basis. The company's Life Science segment experienced a decrease in sales, while the Clinical Diagnostics segment saw a slight increase. Despite a net loss of $3,369.6 million, the underlying strength of the core business is encouraging.
First-quarter net sales were $700.1 million, a 3.7 percent decrease compared to Q1 2021.
Life Science segment net sales decreased by 5.3 percent compared to the same period in 2021.
Clinical Diagnostics segment net sales decreased by 1.9 percent compared to the same period in 2021.
Net loss for the first quarter of 2022 was $3,369.6 million, or a loss of $112.57 per share, on a diluted basis.
Revenue by Segment
Forward Guidance
For the full year 2022, the company continues to anticipate non-GAAP currency-neutral revenue growth of approximately 1.0 to 2.0 percent and an estimated non-GAAP operating margin of approximately 19.0 percent.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...